Figure 1

Identification of highly abundant peptide in human umbilical cord serum and the modification. (A) Size Exclusion Chromatograph of human umbilical cord serum. (B,C) Reversed phase liquid chromatography for the samples from A. (D) Bioactivity analysis for samples isolated from B–C. (E) Mass spectrometry analysis for sample e from B–C. (F) The amino acid sequences of peptides in this study. (G) TOF/TOF Reflect spectrum of VI-13, VI-17 and the control peptide AI-17. (H) CD spectra for VI-17 and the control peptide AI-17.